Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Breast Cancer Research

Volumn 18, Issue 1, 2016, Pages

  Rebbeck, Timothy R ^a   Friebel, Tara M ^a   Mitra, Nandita ^b   Wan, Fei ^c   Chen, Stephanie ^d   Andrulis, Irene L ^g,h   Apostolou, Paraskevi ⁱ   Arnold, Norbert ^j   Arun, Banu K ^k   Barrowdale, Daniel ^e   Benitez, Javier ^l,m   Berger, Raanan ⁿ   Berthet, Pascaline ^o   Borg, Ake ^p   Buys, Saundra S ^q   Caldes, Trinidad ^r   Carter, Jonathan ^s   Chiquette, Jocelyne ^t   Claes, Kathleen B M ^u   Couch, Fergus J ^v   Cybulski, Cezary ^w   Daly, Mary B ^x   de la Hoya, Miguel ^r   Diez, Orland ^y   Domchek, Susan M ^b   Nathanson, Katherine L ^b   Durda, Katarzyna ^w   Ellis, Steve ^z   Evans, D Gareth ^aa   Foretova, Lenka ^ab   Friedman, Eitan ^n,ac   Frost, Debra ^z   Ganz, Patricia A ^ad   Garber, Judy ^a   Glendon, Gord ^ae   Godwin, Andrew K ^af,ag   Greene, Mark H ^ah   Gronwald, Jacek ^w   Hahnen, Eric ^ai   Hallberg, Emily ^aj   Hamann, Ute ^ak   Hansen, Thomas V O ^al   Imyanitov, Evgeny N ^an   Isaacs, Claudine ^ao   Jakubowska, Anna ^w   Janavicius, Ramunas ^ap,aq   Jaworska Bieniek, Katarzyna ^w   John, Esther M ^ar   Karlan, Beth Y ^as   Kaufman, Bella ⁿ   Kwong, Ava ^au,av   Laitman, Yael ^n,ac   Lasset, Christine ^aw   Lazaro, Conxi ^ax   Lester, Jenny ^as   Loman, Niklas ^p   Lubinski, Jan ^w   Manoukian, Siranoush ^ay   Mitchell, Gillian ^at,az   Montagna, Marco ^ba   Neuhausen, Susan L ^bb   Nevanlinna, Heli ^bc   Niederacher, Dieter ^bd   Nussbaum, Robert L ^be   Offit, Kenneth ^bf   Olah, Edith ^bg   Olopade, Olufunmilayo I ^be   Park, Sue Kyung ^bh   Piedmonte, Marion ^bi   Radice, Paolo ^ay   Rappaport Fuerhauser, Christine ^bj   Rookus, Matti A ^am   Seynaeve, Caroline ^bk   Simard, Jacques ^bl   Singer, Christian F ^bj   Soucy, Penny ^bl   Southey, Melissa ^az   Stoppa Lyonnet, Dominique ^bm   Sukiennicki, Grzegorz ^w   Szabo, Csilla I ^bn   Tancredi, Mariella ^bo   Teixeira, Manuel R ^bp   Teo, Soo Hwang ^bq,br   Terry, Mary Beth ^bs   Thomassen, Mads ^bt   Tihomirova, Laima ^bu   Tischkowitz, Marc ^bv   Toland, Amanda Ewart ^bw   Toloczko Grabarek, Aleksandra ^w   Tung, Nadine ^bx   van Rensburg, Elizabeth J ^by   Villano, Danylo ^bf   Wang Gohrke, Shan ^bz   Wappenschmidt, Barbara ^ai   Weitzel, Jeffrey N ^bb   Zidan, Jamal ^ca,cb   Zorn, Kristin K ^be   McGuffog, Lesley ^f   Easton, Douglas ^f   Chenevix Trench, Georgia ^e   Antoniou, Antonis C ^f   Ramus, Susan J ^d,cc   more..

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g MOUNT SINAI HOSPITAL   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l Structural Biology and Biocomputing Programme   (Spain)

^m CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

ⁿ SHEBA MEDICAL CENTER   (Israel)

^o CENTRE FRANÇOIS BACLESSE   (France)

^p LUND UNIVERSITY HOSPITAL   (Sweden)

^q UNIVERSITY OF UTAH   (United States)

^r HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^s SYDNEY CANCER CENTRE   (Australia)

^t LAVAL UNIVERSITY   (Canada)

^u GHENT UNIVERSITY HOSPITAL   (Belgium)

^v MAYO CLINIC   (United States)

^w POMERANIAN MEDICAL UNIVERSITY   (Poland)

^x FOX CHASE CANCER CENTER   (United States)

^y VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^z UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^aa UNIVERSITY OF MANCHESTER   (United Kingdom)

^ab MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^ac TEL AVIV UNIVERSITY   (Israel)

^ad UNIVERSITY OF CALIFORNIA   (United States)

^ae MOUNT SINAI HOSPITAL   (Canada)

^af UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^ag UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^ah NATIONAL CANCER INSTITUTE   (United States)

^ai Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases   (Germany)

^aj MAYO CLINIC   (United States)

^ak GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^al University of Copenhagen   (Denmark)

^am NETHERLANDS CANCER INSTITUTE   (Netherlands)

^an N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^ao GEORGETOWN UNIVERSITY   (United States)

^ap VILNIUS UNIVERSITY   (Lithuania)

^aq State Research Institute Centre for Innovative Medicine   (Lithuania)

^ar CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^as CEDARS SINAI MEDICAL CENTER   (United States)

^at PETER MACCALLUM CANCER CENTRE   (Australia)

^au HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^av UNIVERSITY OF HONG KONG   (Hong Kong)

^aw CENTRE LÉON BÉRARD   (France)

^ax BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^ay NATIONAL CANCER INSTITUTE   (Italy)

^az UNIVERSITY OF MELBOURNE   (Australia)

^ba VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^bb CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^bc HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^bd UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^be Department of Population Sciences ^*  (United States)

^bf MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^bg NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^bh Seoul National University College of Medicine   (South Korea)

^bi ROSWELL PARK CANCER INSTITUTE   (United States)

^bj MEDICAL UNIVERSITY OF VIENNA   (Austria)

^bk ERASMUS MC CANCER INSTITUTE   (Netherlands)

^bl University Laval   (Canada)

^bm INSTITUT CURIE   (France)

^bn NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^bo UNIVERSITY HOSPITAL OF PISA   (Italy)

^bp PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^bq CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^br UNIVERSITY OF MALAYA   (Malaysia)

^bs Department of Genetics ^*  (United States)

^bt ODENSE UNIVERSITY HOSPITAL   (Denmark)

^bu LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^bv MCGILL UNIVERSITY   (Canada)

^bw OHIO STATE UNIVERSITY   (United States)

^bx BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^by UNIVERSITY OF PRETORIA   (South Africa)

^bz UNIVERSITY HOSPITAL ULM   (Germany)

^ca Rebecca Sieff Government Hospital   (Israel)

^cb BAR ILAN UNIVERSITY   (Israel)

^cc UNIVERSITY OF NEW SOUTH WALES   (Australia)

more..

Author keywords

BRCA1; BRCA2; Hereditary breast and ovarian cancer; Transheterozygosity

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INHERITANCE; JEW; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; MUTATIONAL ANALYSIS; OVARY CANCER; PHENOTYPE; PROTEIN EXPRESSION; TRANSHETEROZYGOTE; TUMOR SUPPRESSOR GENE; ALLELE; BREAST TUMOR; CLINICAL TRIAL; EXON; GENETICS; GERMLINE MUTATION; HEALTH SURVEY; MULTICENTER STUDY; PATHOLOGY; PROMOTER REGION;

ALLELES; BREAST NEOPLASMS; EXONS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; LOSS OF HETEROZYGOSITY; PHENOTYPE; POPULATION SURVEILLANCE; PROMOTER REGIONS, GENETIC;

EID: 85000995840     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-016-0768-3     Document Type: Article

References (39)

1. Bell DW, Erban J, Sgroi DC, Haber DA. Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res. 2002;62(10):2741-3.
2. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8(4):R38.
3. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick RB, Aaltonen LA, de la Chapelle A. Semiautomated assessment of loss of heterozygosity and replication error in tumors. Cancer Res. 1996;56(14):3331-7.
4. Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, et al. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 2006;66(4):2019-27.
5. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 2007a;9(2):104
6. Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W, Daly PA, Ford D, Easton DF. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene. 1995;10(8):1673-5.
7. Cornelis RS, Neuhausen SL, Johansson O, Arason A, Kelsell D, Ponder BA, Tonin P, Hamann U, Lindblom A, Lalle P. High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer. 1995;13(3):203-10.
8. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967-75.
9. Domchek SM, Tang JB, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro AN, Messick TE, Powers J, Yonker A, et al. Biallelic Deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov. 2013;3(4):399-405.
10. Dworkin AM, Spearman AD, Tseng SY, Sweet K, Toland AE. Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam Cancer. 2009;8(4):339-46.
11. Friedman E, Bar-Sade Bruchim R, Kruglikova A, Risel S, Levy-Lahad E, Halle D, Bar-On E, Gershoni-Baruch R, Dagan E, Kepten I, et al. Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet. 1998;63(4):1224-7.
12. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet. 2004;75(4):535-44.
13. Gudmundsson J, Johannesdottir G, Bergthorsson JT, Arason A, Ingvarsson S, Egilsson V, Barkardottir RB. Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. Cancer Res. 1995;55(21):4830-2.
14. Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, Niederacher D, Goecke TO, Doelken SC, Dikow N, et al. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat. 2012;134(3):1229-39.
15. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297(5581):606-9.
16. Khalique L, Ayhan A, Weale ME, Jacobs IJ, Ramus SJ, Gayther SA. Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol. 2007;211(3):286-95.
17. Khoo US, Chan KY, Cheung AN, Xue WC, Shen DH, Fung KY, Ngan HY, Choy KW, Pang CP, Poon CS, et al. Recurrent BRCA1 and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutat. 2002;19(3):307-8.
18. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-6.
19. King TA, Li W, Brogi E, Yee CJ, Gemignani ML, Olvera N, Levine DA, Norton L, Robson ME, Offit K, et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol. 2007;14(9):2510-8.
20. Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. Ann Oncol. 2011;22(4):964-6.
21. Liede A, Rehal P, Vesprini D, Jack E, Abrahamson J, Narod SA. A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2. Am J Hum Genet. 1998;62(6):1543-4.
22. Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006;25(43):5875-84.
23. Merajver SD, Frank TS, Xu J, Pham TM, Calzone KA, Bennett-Baker P, Chamberlain J, Boyd J, Garber JE, Collins FS. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer. Clin Cancer Res. 1995;1(5):539-44.
24. Meric-Bernstam F. Heterogenic loss of BRCA in breast cancer: the "two-hit" hypothesis takes a hit. Ann Surg Oncol. 2007;14(9):2428-9.
25. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71.
26. Miolo G, Puppa LD, Santarosa M, De Giacomi C, Veronesi A, Bidoli E, Tibiletti MG, Viel A, Dolcetti R. Phenotypic features and genetic characterization of male breast cancer families: identification of two recurrent BRCA2 mutations in north-east of Italy. BMC Cancer. 2006;6:156.
27. Ramus SJ, Friedman LS, Gayther SA, Ponder BA, Bobrow L, van der Looji M, Papp J, Olah E. A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nat Genet. 1997;15(1):14-5.
28. Randall TC, Bell KA, Rebane BA, Rubin SC, Boyd J. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient. Gynecol Oncol. 1998;70(3):432-4.
29. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89.
30. Sawyer SL, Tian L, Kähkönen M, Schwartzentruber J, Kircher M, Majewski J, Dyment DA, Innes AM, Boycott KM, Moreau LA, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 2015;5(2):135-42.
31. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet. 1992;2(2):128-31.
32. Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA, Ramus SJ. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008;14(12):3761-7.
33. Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, Vooijs M, van Diest PJ. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol. 2008;19(11):1870-4.
34. Tapia T, Smalley SV, Kohen P, Muñoz A, Solis LM, Corvalan A, Faundez P, Devoto L, Camus M, Alvarez M, et al. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics. 2008;3(3):157-63.
35. Tesoriero A, Andersen C, Southey M, Somers G, McKay M, Armes J, McCredie M, Giles G, Hopper JL, Venter D. De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet. 1999;65(2):567-9.
36. Tsongalis GJ, Linfert DR, Johnson RC, Ackroyd R, Berman MM, Ricci A. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient. Arch Pathol Lab Med. 1998;122(6):548-50.
37. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-44.
38. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088-90.
39. Zuradelli M, Peissel B, Manoukian S, Zaffaroni D, Barile M, Pensotti V, Cavallari U, Masci G, Mariette F, Benski AC, et al. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Breast Cancer Res Treat. 2010;124(1):251-8.